Cytune Pharma's Corporate Minority Round

Cytune Pharma raised a round of funding on February 04, 2015.

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's compound, CYP 0150, is a human interleukin-15 linked to its effector.…

Articles about Cytune Pharma's Corporate Minority Round: